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Liquid chromatography–mass spectrometry method for the analysis
of the anti-cancer agent capecitabine and its nucleoside metabolites
in human plasma
Yan Xu , Jean L. Grem

Abstract
A reversed-phase high-performance liquid chromatography method with electrospray ionization and mass spectral
detection is described for the determination of capecitabine, 59-deoxy-5-fluorocytidine and 59-deoxy-5-fluorouridine in
human plasma with 5-chloro-29-deoxyuridine as the internal standard. An on-line sample clean-up procedure allows dilution
of the plasma sample with the initial mobile phase. The linear dynamic range is 0.0500–10.0 mg / ml for capecitabine, and
0.0500–25.0 mg / ml for the metabolites, 59-deoxy-5-fluorocytidine and 59-deoxy-5-fluorouridine, respectively. This method
has been used to analyze plasma samples from patients receiving capecitabine in combination with oxaliplatin.
Published by Elsevier Science B.V.
Keywords: Capecitabine; 5-Deoxy-5-fluorocytidine; 5-Deoxy-5-fluorouridine

Introduction
Capecitabine
(N 4 -pentoxycarbonyl-59-deoxy-5fluorocytidine, Xeloda) is the first oral prodrug of
5-fluorouracil (5-FU) to be approved in the United
States, based on its activity in patients with metastatic breast cancer whose disease has progressed
after two prior chemotherapy regimens [1,2]. The

drug has also been approved for treatment of patients
with metastatic colorectal cancer [3,4]. This agent is
absorbed intact as the parent drug through the
gastrointestinal mucosa, and then undergoes a threestep enzymatic conversion that results in the release
of 5-FU [5]. Hepatic carboxylesterase yields 59deoxy-5-fluorocytidine (59-DFCR), which is then
converted by cytidine deaminase, a widely distributed enzyme in plasma and tissues, to 59-deoxy-5fluorouridine (59-DFUR); finally, thymidine phosphorylase generates 5-FU (Fig. 1). 5-FU is enzymatically cleared from plasma, and the initial, rate-limiting step is catalyzed by dihydropyrimidine dehydrogenase to produce dihydro-5-fluorouracil; two subsequent steps result in the formation of fluoroureidopropionic acid and a-fluoro-b-alanine (FBAL),
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Fig. 1. Metabolism of capecitabine. The enzymes are as follows: 1, carboxylesterase; 2, cytidine deaminase; 3, thymidine phosphorylase; 4,
dihydropyrimidine dehydrogenase; 5, dihydropyrimidinase; 6, b-alanine synthase.

respectively, with release of CO 2 and NH 3 [6].
Although FBAL does not have anti-cancer activity, it
is thought to contribute to some host toxicities.
Clinical studies have documented rapid gastrointestinal absorption of the parent drug with efficient
conversion to 59-DFUR [7,8]. Systemic levels of
5-FU have generally been about fivefold lower on a
molar basis than the plasma levels of the parent
compound, providing evidence of intracellular formation of 5-FU.
The most commonly used clinical schedule involves administration of capecitabine daily for 14
days every 3 weeks, and the recommended single
agent dose is 2500 mg / m 2 p.o. daily given as two
equal doses about 12 h apart, taken within 30 min
after a meal. Dose-limiting toxicities include diarrhea, nausea, vomiting, and palmar-plantar erythrodysesthesia, while myelosuppression is uncommon
[1–4].
The pharmacokinetics of capecitabine, 59-DFCR,
and 59-DFUR were initially measured by a liquid
chromatography method with ultraviolet detection
developed by the pharmaceutical sponsor, while the
the pharmacokinetics of 5-FU and its catabolites
were measured by gas chromatography with mass
spectral detection (GC–MS) [9]. The time at which
the maximum plasma concentrations (Cmax ) for
capecitabine, the nucleoside metabolites and 5-FU
are reached has varied among patients, ranging from
0.5 to 3 h after oral dosing. The apparent elimination
half-lives (t 1 / 2 ) are |1 h for all metabolites except
for FBAL, which has an initial half-life of about 2.6
h. The area under the plasma concentration–time
curve (AUC) of 59-DFUR is reported to be about
threefold higher than that of 59-DFCR when the
peripheral blood samples are collected in the absence

of a cytidine deaminase inhibitor. Over the dose
range used clinically, there is no evidence of dosedependency in the pharmacokinetic parameters.
In conjunction with an ongoing phase I clinical
trial that employs escalating doses of capecitabine in
combination with oxaliplatin, we plan to measure the
pharmacokinetics of capecitabine given alone and
with oxaliplatin. The methods initially developed by
Roche Laboratories used two different liquid chromatography columns and separation conditions for
the analysis of capecitabine and 59-DFCR / 59-DFUR,
respectively [9]. A proprietary liquid chromatography tandem mass spectrometry (LC–MS–MS)
method was subsequently developed by Roche Laboratories; sufficient details have not been provided to
permit exact replication of the method [10]. Further,
MS–MS is a relatively expensive technology, while
mass spectral detection with a single quadrupole is
more often available in a research laboratory setting.
We describe herein a combined analytical method
that permits the simultaneous measurement of plasma capecitabine, 59-DFCR, and 59-DFUR with direct
sample injection. This method involves on-line plasma sample extraction, reversed-phase liquid chromatographic separation, and electrospray-ionization
mass spectrometric detection that is suitable for
analysis of plasma samples from patients receiving
capecitabine therapy.

Experimental
Chemicals and solutions
Ammonium acetate (99.999%) was from Aldrich
(Milwaukee, WI, USA). HPLC grade water was from
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Fisher (Fair Lawn, NJ, USA). High purity acetonitrile (Cat. no. 015-4) and methanol (Cat. no. 230-4)
were from Burdick & Jackson (Muskegon, MI,
USA). 59-DFUR (C 9 H 11 FN 2 O 4 , Mw 246.2, CAS
registry 3094-09-5), 5-chloro-29-deoxyuridine (5CUDR), 5-fluorouridine (FUR), and 5-fluoro-29-deoxyuridine (5-FUDR) were from Sigma (St. Louis,
MO, USA). Capecitabine (C 15 H 22 FN 3 O 6 , Mw 359.4,
CAS registry 154361-50-9; lot no. 26954-190AMIL) and 59-DFCR (C 9 H 12 FN 3 O 3 , Mw 245.2, Ro
21-8782, lot no. 5206-262) were generously provided by Hoffmann-La Roche (Nutley, NJ, USA).
Tetrahydrouridine (lot no. 112907-J / 22) was provided by the Drug Synthesis and Chemistry Branch,
Division of Cancer Treatment and Diagnosis, National Cancer Institute (Bethesda, MD, USA). Pooled
donor human plasma was obtained from the Department of Transfusion Medicine in the Clinical Center,
National Institutes of Health (Bethesda, MD, USA).
A stock solution of ammonium acetate (100 mM,
pH 6.8) was prepared by dissolving appropriate
amounts of ammonium acetate in a known volume of
HPLC grade water, and 5 mM ammonium acetate at
pH 6.8 was prepared by 1:20 dilution of the stock
solution with HPLC grade water and used as the
solvent A in the gradient elution. Acetonitrile was
used as the solvent B (Table 1).
Standard stock solutions of capecitabine, 59-DFCR
and 59-DFUR at the concentration of 10.0 mg / ml,
and internal standard stock solution of 5-CUDR at
the concentration of 500 mg / ml were prepared by
dissolving appropriate amounts of compounds in a
known volume of methanol. Standard mixture working solutions of capecitabine, 59-DFCR and 59DFUR at the concentrations of 0.50, 1.00, 5.00, 10.0,
50.0, 100, 200 and 500 mg / ml were prepared by
mixing and serial dilutions of the stock solutions
with methanol. An internal standard working solution at the concentration of 50.0 mg / ml was prepared
by a 10-fold dilution of the stock solution with
methanol.
Blood sampling
The blood samples were collected from colorectal
cancer patients participating in an Institutional Review Board-approved phase I clinical study of oral
capecitabine alone and with oxaliplatin. All patients

Table 1
Gradient elution method
Time (min)

%A

%B

Flow (ml / min)

Curve

0.0
0.8
1.0
2.0
2.2
10.0
12.0
15.0
15.2
20.0
20.2
21.2
21.4
24.0

100
100
100
100
90
70
30
30
100
100
5
5
100
100

0
0
0
0
10
30
70
70
0
0
95
95
0
0

3.0
3.0
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
3.0
3.0
3.0
3.0

1
1
1
1
6
6
6
1
6
1
6
1
6
11

Solvent A, 5 mM ammonium acetate at pH 6.8; solvent B,
acetonitrile. See Waters 2690 Separations Module Operator’s
Guide, Table 6.4. The specified curve number sets the rate at
which the solvent is to change to the new proportions and / or
flow-rate: curve number 6 is a linear gradient; curves 1 and 11 are
step gradients that proceed instantaneously from initial to final
conditions either at the start or end of the time interval.

gave written, informed consent. For the pharmacokinetic studies, blood samples were obtained
from an indwelling intravenous cannula (heparin
lock) prior to dosing, and then 0.5, 1, 2, 3, 4, 6 and 8
h after the initial dose of capecitabine given alone,
and again on the first day of the second cycle in
which oxaliplatin was given as a 2-h infusion by vein
prior to the oral dose of capecitabine. The blood
samples were collected in 10-ml green-top
Vacutainer姠 tubes (Becton Dickinson, Franklin
Lakes, NJ, USA) containing sodium heparin and 10
nmol tetrahydrouridine, an inhibitor of cytidine
deaminase (Ki 10 27 M). The samples were immediately placed on ice and transported to the laboratory,
where they were centrifuged for 10 min at 800 g
(4 8C). The plasma was transferred into three labeled
2.0-ml cryogenic vials (Nalge Nunc, Rochester, NY,
USA) and stored at 270 8C until analysis.
Preparation of blank plasma, calibrators and
patient samples
Pooled human plasma from voluntary blood
donors containing 1 mM tetrahydrouridine was used
as the blank plasma in this study. Fifty ml of a
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standard mixture solution of capecitabine, 59-DFCR
and 59-DFUR at each concentration level and 50 ml
of the internal standard solution (5-CUDR, 50.0
mg / ml) were added to 1.5-ml centrifuge tubes
(Marsh Bio Products, Rochester, NY, USA). The
solutions were dried in an Eppendorf Vacufuge
concentrator (Brinkmann Instruments, Westbury, NY,
USA) at 30 8C for 20 min. Then, aliquots of blank
plasma (500 ml each) were added. For the patient
samples, 50 ml internal standard solution (5-CUDR,
50.0 mg / ml) alone were added to 1.5-ml centrifuge
tubes, and the solution was dried in an Eppendorf
Vacufuge at 30 8C for 20 min. Aliquots of patient
plasma (500 ml each) were then added.
The above blank plasma, calibrators, and patient
samples were diluted with equal volumes of 5 mM
ammonium acetate (pH 6.8). After vortex mixing,
these samples were put on ice for 15 min before
centrifugation at 3000 g at 41 8C for 10 min. The
sample solutions were transferred to autosampler
vials (Waters, part no. 186000326), taking care to
avoid any fat floating on the top and the precipitate,
followed by instrument analysis.
Recovery studies
The recoveries of capecitabine, 59-DFCR, 59DFUR and 5-CUDR were determined by comparing
the mean of peak areas of the plasma samples
prepared from blank plasma spiked with the compounds at three concentration levels (0.250, 2.50 and
25.0 mg / ml) to the mean of the peak areas of the
control samples prepared from 5 mM ammonium
acetate (pH 6.8) spiked with analytes and internal
standard at the same levels. The sample preparation
procedure was the same as those described for the
calibrators (see Section 2.3).

Deerfield, IL, part no. 85526), and a PC station with
MassLynx NT (Version 3.4) software (Micromass,
Manchester, UK) for data acquisition. The fluid
processor was electrically connected to switch 4 of
the I / O signal connector A in the rear panel of the
Waters 2690 separations module. The fluidic connection of the system is shown in Fig. 2. At position
A, the eluent from the pump carried the sample from
the autosampler to the extraction column (Waters
Oasis姠 HLB cartridge column, 2.1 mm320 mm,
part no. 186000706) and the sample matrix was
excluded to the waste. At position B, the gradient
eluent from the pump eluted the analytes and the
internal standard from the extraction column and
carried them through the C 18 guard column
(SecurityGuard姠, part no. KJO-4282, Phenomenex,
Torrance, CA, USA) to the analytical column (Wa˚ 2.0 mm3150 mm,
ters YMC ODS-AQ 5 mm, 120 A,
part no. AQ12S051502WT). The eluate of the analytical column was diverted to the mass spectrometer
(ESI-MS detector) and the spectrophotometer (PDA
detector) via a PEEK microvolume connector (Cat.
no. MT1XCPK, Valco Instruments, Houston, TX)
with a post-column split ratio of 1:2. The smaller
flow went to the ESI-MS detector and the larger one
to the PDA detector. High pressure PEEK tubing was
used for all connections. The tubing prior to the inlet
of the analytical column was 1 / 16 inch O.D. and
0.01 inch I.D., and the one after the analytical
column was 1 / 16 inch O.D. and 0.005 inch I.D.

Instrumentation
The system used for this work could perform the
following tasks: (a) on-line sample extraction, (b) LC
separation, and (c) ESI-MS and UV detection. The
system included a Waters 2690 separations module, a
Waters 996 photodiode array (PDA) detector, a
Micromass Platform LC mass spectral detector (Waters, Milford, MA, USA), a Rheodyne LabPRO twoposition (6-Port, PEEK) fluid processor (Alltech,

Fig. 2. Block diagram of the instrument system. Position A
(dashed line), for the on-line sample extraction; position B (solid
line), for the LC–ESI-MS detection.
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Chromatographic conditions
The operation conditions of Waters 2960 separations module were set as follows: sample temperature, 41 8C; analytical column temperature, 30 8C;
extraction column temperature, ambient; sample
injection volume, 20 ml. The method used gradient
elution for on-line sample extraction and LC–MS
analysis with a total run time of 24 min (Table 1).
The switching valve of the fluid processor diverted
the effluent of the extraction column to the waste for
the first eight-tenths of a minute to prevent plasma
proteins and other polar matrix interferences from
entering the analytical column (position A, Fig. 2).
The valve was switched to the position B at the
eight-tenth min to redirect the flow to the analytical
column. The valve was switched back to the initial
position (position A) at 19.90 min for re-conditioning the extraction column.
ESI-MS detection
The mass spectrometer was operated in both the
positive and the negative modes of electrospray
ionization (ESI1 and ESI2). It was tuned by the
infusion of an analyte mixture (50.0 mg / ml each in 5
mM ammonium acetate, pH 6.8) with a Harvard
syringe pump (Harvard Apparatus, South Natick,
MA, USA, Cat. no. 55-1111) at a flow-rate of 10
ml / min via 0.005 inch I.D. PEEK tubing. The
sample was converged with the incoming LC mobile
phase (5 mM ammonium acetate, pH 6.8 at flow-rate
of 0.2 ml / min) in a sample tee prior to delivery into
the MS detector. The optimized ionization conditions
are summarized in Table 2.
Full scan spectra were acquired in the centroid
Table 2
Electrospray ionization conditions
Parameters
Analytical vacuum
Nitrogen gas
Capillary
Cone
Source heater
LM resolution
HM resolution
Ion energy

ESI1
,1.0310
400 l / h
3.50 kV
220 kV
140 8C
14.5
14.5
0.3 V

ESI2
24

mBar

,1.0310 24 mBar
400 l / h
2.70 kV
35 V
140 8C
15.0
15.5
0.8 V

mode over the mass range of 200–400 amu at the
scan rate of 200 amu / s. Single-ion-monitoring (SIM)
mode was used for sample quantitation by sequentially monitoring quasi-molecular ions of each analyte: m /z 245, [59-DFUR2H] 2 ; m /z 246, [59DFCR1H] 1 ; m /z 261, [5-CUDR2H] 2 ; and m /z
360, [capecitabine1H] 1 . Data acquisition was carried out with a dwell time of 0.50 s, a span of 0.00
Da, repeats of 1, and inter-channel delay of 0.05 s.
The cone voltages were 35, 15, 35 and 20 V for ion
masses 245, 246, 261 and 360, respectively.
Data analysis
The plasma concentrations were determined by
comparing the peak area ratios for each analyte of
interest to the internal standard in the patient samples
to the ratios generated from the calibration curve.
Non-compartmental methods were used to analyze
the clinical sample data using WinNonLin Pro
version 3.2 (Pharsight Corp., Mountain View, CA,
USA). The AUC was determined by the linear
trapezoidal rule, and the half-life was estimated from
the terminal portion of the curve.

Results and discussion
Sample preparation
In this work, the blank plasma, calibrators, and
patient samples were first diluted with equal volumes
of 5 mM ammonium acetate, pH 6.8. Then, the
sample solutions were mixed, iced, and centrifuged
before transferring to autosampler vials for the LC–
ESI-MS analysis.
After these steps, some of the patient plasma
samples had a whitish floating layer (probably fat)
and a precipitate (probably fibrin). These phenomena
were not observed with the blank plasma samples; a
reasonable explanation may be that the blank plasma
was, in general, from young healthy donors, while
the blood samples were from older cancer patients
who had taken capecitabine within 30 min after a
meal. Care was taken during the transfer of the
diluted supernatant to the autosampler vial to avoid
the precipitate and the globular material on the
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surface. To prevent experimental errors, the same
procedures were used in the preparation of blank
plasma, calibrators, and patient plasma samples.
On-line sample extraction
An on-line sample extraction is an in situ solidphase extraction, which includes loading of the
sample, exclusion of macromolecules while retaining
the analytes, followed by elution of the analytes. A
major advantage of on-line sample extraction over
off-line solid-phase extraction (SPE) or liquid–liquid
extraction in plasma sample preparation is that direct
sample injection requires minimum sample handling,
improves sample throughput and reproducibility, and
is ready for automation.
Because of the hydrophilic and lipophilic nature of
the nucleosides, an Oasis HLB cartridge column was
used as the extraction column for the on-line sample
preparation. Based on the product information,
Oasis姠 HLB sorbent is a copolymer of [poly(divinylbenzene-co-N-vinylpyrrolidone)]. HLB is an

acronym for hydrophilic lipophilic balance that
describes the dual retention capability of the sorbent
to retain polar and non-polar compounds. The waterwettable macroporous sorbent of Oasis姠 HLB can
exclude plasma proteins and other matrix constituents, while retaining the analytes of interest
under the optimized conditions with high and reproducible recoveries.
Fig. 3 shows the gradient elution profiles of the
extraction cartridge with the eluent directed to the
photodiode array detector. These profiles indicate
that plasma proteins and other macromolecules could
be excluded from the column within 48 s after the
sample injection, whereas capecitabine, 59-DFCR,
59-DFUR, 5-CUDR (I.S.) and other endogenous
compounds did not elute before 7 min. For the first
0.8 min after the sample injection, the column
effluent was diverted to the waste; thereafter, the
switching valve controlled by the MassLynx NT
software was turned to position B, which was in-line
with the guard column, the analytical column, and
the ESI-MS detector. The analytes of interest to-

Fig. 3. Elution profiles of analytes in 5 mM ammonium acetate, pH 6.8 (bottom trace), blank plasma (middle trace), and analytes in blank
plasma (top trace) from Oasis姠 HLB cartridge column. The instrument system was in position B, except the guard and analytical columns
were removed; PDA detection was set over the range of 200–400 nm, the analytes were at 25.0 mg / ml each and the gradient elution method
outlined in Table 1 was employed.
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gether with other endogenous compounds were
eluted from the extraction column by the gradient of
5 mM ammonium acetate (pH 6.8) and acetonitrile
(Table 1), separated on the analytical column, and
detected by the ESI-MS detector.
In the method developed, at 19.90 min after the
sample injection, the switching valve was changed to
divert the eluate to the waste, and the extraction
column was then flushed with 95% acetronitrile–5%
5 mM ammonium acetate and equilibrated with 5
mM ammonium acetate (the extraction buffer). Due
to the sufficient washing prior to the next sample
injection, no analyte carryover was observed in this
method.

ESI-MS detection
The full-scan mass spectra of capecitabine, 59DFCR, 59-DFUR, and 5-CUDR are shown in Fig. 4.
From these spectra, it is apparent that higher detection sensitivities could be achieved by monitoring
quasi-molecular ions [capecitabine1H] 1 at m /z 360,
[59-DFCR1H] 1 at m /z 246, [59-DFUR2H] 2 at m /z
245. Therefore, these ions were chosen for quantitation in the subsequent studies. For internal standard
(5-CUDR), the negative full-scan produced a much
cleaner mass spectrum than the positive one with
comparable detection sensitivity. Hence, [5-CUDR2
H] 2 at m /z 261 was used for the subsequent
analyses. Single-ion-monitoring (SIM) mode was
used for quantitative analysis. The specificity for
detecting capecitabine, 59-DFCR, 59-DFUR, and 5CUDR is illustrated by the representative mass
chromatograms from human plasma in Fig. 5. Coeluting endogenous compounds (i.e. the unknowns)
and other potential interfering metabolites (i.e. 5FUDR and 5-FUR) could be separated by the proper
chromatographic conditions.

Chromatographic conditions
A useful analytical method should permit resolution and detection of the analytes of interest and
the internal standard from other interfering metabolites and co-eluting endogenous compounds. In this

work, since 5-DFCR shares the same mass-to-charge
(m /z) ratio with an unknown, 5-DFUR shares the
same m /z ratio with 5-FUDR, and 5-CUDR shares
the same m /z ratio with 5-FUR and an unknown
(Fig. 5), the separation of these compounds directly
affected the selectivity and specificity of the analytical method. Among the analytes of interest,
except for capecitabine, the other compounds are
quite hydrophilic in nature. Since these compounds
elute rapidly from reversed-phase columns with
mobile phases containing a low percentage of organic content, they presented a challenge to the
chromatographic method development.
For this work, we had tested several reversedphase columns for the separation of the analytes
from the interfering compounds, which include Symmetry C 18 , YMC Basic, XTerra C 18 , Nova-Pak C 18 ,
and YMC ODS-AQ columns (Waters Corporation).
Best results were obtained with the YMC ODS-AQ
column. ODS-AQ is a reversed-phase material that is
prepared with a monomeric bonding of octadecylsilane (ODS) followed by addition of a hydrophilic endcapping reagent. The hydrophilic endcap
creates a surface that can be wetted with polar
eluents and does not undergo phase collapse even in
100% water. In aqueous acidic conditions, the hydrophilic endcap may protect the silane bond from
hydrolysis and results in a longer lifetime. Because
there are more C 18 chains available for interaction,
ODS-AQ material has stronger retention to polar
compounds than conventionally endcapped ODS
materials in aqueous mobile phases.
In LC–ESI-MS, the choices of mobile phase
composition, pH, and flow-rate are restrained by the
conditions that are suitable for both LC separation
and ESI-MS detection. In general, ESI-MS requires
the use of volatile solvent additives to prevent
clogging of the sample orifice. The solvent additives
do not neutralize the analyte ions in gaseous phase
by ion pairing, and can control the pH of the mobile
phase to promote the formation of analyte ions.
A gradient elution method that uses both 5 mM
ammonium acetate (pH 6.8) and acetonitrile as
solvents has been optimized with the consideration
of on-line sample extraction, LC separation, and
ESI-MS detection. For example, although the use of
1% acetic acid as mobile phase A in the gradient
elution method resulted in good LC separation, its
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Fig. 4. Full-scan mass spectra of capecitabine, 59-deoxy-5-fluorocytidine, 59-deoxy-5-fluorouridine and 5-chloro-29-deoxyuridine delivered directly to the MS detector. The
analyte concentration was 250 ng / ml, the flow injection carrier fluid was 5 mM ammonium acetate, pH 6.8, and the flow-rate was 0.1 ml / min.
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Fig. 5. Representative SIM chromatograms of plasma spiked to give a final concentration of 10.0 mg / ml each for capecitabine, 59-DFCR
and 59-DFUR, 20.0 mg / ml each for 5-FdUrd and 5-FUrd, and 2.50 mg / ml for 5-CdUrd. The injection volume was 20 ml. The experimental
conditions are described in Section 2.7. The unknown peaks at 11.99 min (m /z 246) and 13.32 min (m /z 261) have mass spectra that are
distinct from the compounds of interest.

use in the preparation and dilution of the calibrator
and samples did not result in reproducible peak areas
for the parent compound, which might be caused by
capecitabine degradation under the acidic conditions.
Analytical performance
The recovery of the compounds of interest from
plasma was compared to the identical concentrations
prepared directly in mobile phase without further
processing (Table 3). The average recoveries were
99.0%, 99.0%, 73.8% and 81.4% for capecitabine,
5-DFCR, 5-DFUR and 5-CUDR, respectively, and

these values were quite consistent throughout the
concentration range studied (0.250–25.0 mg / ml).
The intra- and inter-assay precision of the method
was determined using plasma calibrators of
capecitabine, 5-DFCR and 5-DFUR at three concentration levels, and three replicates were assayed
for each data point (Table 4). The method had
excellent intra- and inter-assay precision for
capecitabine, 5-DFCR and 5-DFUR, which ranged
from 0.4% to 4.1% and 0.8% to 6.1%, respectively.
Good linear relationships were found between the
peak-area ratios of the analytes to 5-CUDR over the
concentration range of 0.0500–10.0 mg / ml for

Table 3
Recovery of capecitabine, 59-DFCR, 59-DFUR and 5-CUDR from human plasma
Compounds

Capecitabine
59-DFCR
59-DFUR
I.S.

0.25 mg / ml

2.5 mg / ml

25.0 mg / ml

% Recovery

% C.V.

% Recovery

% C.V.

% Recovery

% C.V.

99.0
99.1
74.8
81.6

0.8
6.1
1.4
0.8

100.0
100.4
73.4
81.9

2.8
1.1
2.6
1.2

98.0
97.4
73.1
80.8

6.3
2.4
3.1
0.9

The concentration of the internal standard (5-CUDR) was at a fixed concentration of 2.5 mg / ml. Samples at each concentration were
prepared in triplicate.
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Table 4
Intra- and inter-assay precision for plasma samples
Compounds

0.25 mg/ml

2.5 mg/ml

Peak area

SD

% C.V.

Peak area

Intra-run
Capecitabine
59-DFCR
59-DFUR
5-CUDR

469,301
11,147
14,857
159,163

3603
457
414
432

0.8
4.1
2.8
0.3

3,760,443
127,202
174,039
163,398

Between-run
Capecitabine
59-DFCR
59-DFUR
5-CUDR

471,069
11,662
15,554
160,747

3640
710
211
133

0.8
6.1
1.4
0.8

3,729,965
127,642
172,212
165,547

25.0 mg/ml
SD

% C.V.

Peak area

SD

% C.V.

31,566
1834
710
1340

0.8
1.4
0.4
0.8

20,439,533
1,154,284
1,670,678
166,771

194,849
44,847
10,057
1980

1.0
3.9
0.6
1.2

102,646
1400
4540
4986

2.8
1.1
2.6
1.2

20,470,941
1,176,086
1,628,049
162,034

273,124
70,802
38,040
2360

1.3
6.0
2.3
1.5

The data, shown as the mean6SD, represent samples prepared in triplicate injected either during the same run or on 3 different days. The
concentration of the internal standard, 5-CUDR, was constant at 2.5 mg / ml.

capecitabine, and 0.0500–25.0 mg / ml for 5-DFCR
and 5-DFUR. The correlation coefficients for each of
the calibration curves were above 0.99.
The limits of quantitations defined as 10 times the
signal-to-noise ratio were 0.0278 ng or 1.40 ng / ml
for plasma capecitabine, 0.352 ng or 17.6 ng / ml for
plasma 5-DFCR, and 0.167 ng or 8.40 ng / ml for
plasma 5-DFUR with an injection volume of 20 ml
(Fig. 6). These limits of quantitation were substantially lower than those of the current LC–UV
methods [9].
Pharmacokinetic studies
Blood samples collected prior to dosing indicated
that endogenous compounds did not interfere with
the analyses. MassLynx NT software was used to
calculate the concentration of capecitabine, 5-DFCR,
and 5-DFUR based on the peak area ratios of
capecitabine, 5-DFCR, and 5-DFUR with the internal
standard 5-CdUrd. A representative profile of these
compounds in human plasma is shown in Fig. 7, and
a summary of the pharmacokinetic parameters following the initial dose of capecitabine in four
patients is shown in Table 5. In contrast to previous
reports, we found that the AUC of 59-DFCR was at
least as high or higher than that of 59-DFUR, which
is likely explained by our use of a cytidine deaminase inhibitor in the blood collection tubes. These
results indicate that the LC–ESI-MS method de-

veloped can be used to accurately quantitate the
plasma concentrations of capecitabine, 5-DFCR, and
5-DFUR.

Conclusion
Roche Laboratories has reported two different
methods for the analysis of capecitabine, 59-DFCR
and 59-DFUR in human plasma samples. In both
methods, 0.5 ml plasma is deproteinized with 1 ml
acetonitrile; after vortex-mixing and centrifugation,
the supernatant is subjected to C 18 solid-phase
extraction, and the eluent is concentrated to dryness.
With the LC–UV method, two distinct chromatography columns and separation conditions were required to detect either capecitabine or its two nucleoside metabolites. With the LC–MS–MS method,
the residue obtained from SPE containing
capecitabine, 59-DFCR and 59DFUR was re-suspended in 100 ml ammonium acetate, and 25 ml were
injected into an LC system equipped with a Supelcosil ABS1 C 18 column (150 mm32.0 mm) and a
gradient mobile phase containing 10 mM ammonium
formate–acetonitrile. Further details were not provided, making it problematic for a non-affiliated
laboratory to reproduce the method.
We felt it was important to plan for the analysis of
any possible pharmacokinetic interactions between
capecitabine and oxaliplatin for our phase I trial. To
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Fig. 6. SIM chromatograms of blank plasma and plasma calibrators containing capecitabine, 59-DFCR and 59-DFUR. Analyte
concentrations, 50 ng / ml; injection volume, 20 ml; 1 ng injected. Experimental conditions were the same as Fig. 5.
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Fig. 7. Profiles of the plasma concentrations of capecitabine, 59-DFCR and 59-DFUR determined by the LC–ESI-MS method are shown for
subject 18 following capecitabine 1650 mg (750 mg / m 2 ) alone (left panel) or immediately following a 2-h intravenous infusion of
oxaliplatin 130 mg / m 2 (right panel).

enable this analysis, we developed a novel, validated
LC–MS assay that is capable of simultaneously
measuring capecitabine, 5-DFCR and 5-DFUR in
human plasma with direct sample injection. Compared to the off-line sample preparations previously
described, our on-line sample clean-up offers an
advantage in terms of efficiency, precision, and cost.
Since the method has comparable linear dynamic

ranges, sensitivity, high precision, and excellent
analyte recoveries, it offers a viable alternative to the
proprietary methods. Our method has successfully
been used in the analysis of plasma samples from
patients participating in a phase I clinical trial of
escalating doses of capecitabine ranging from 1300
to 3300 mg given twice per day (total 2600–6600
mg per day).

Table 5
Pharmacokinetic parameters

T max (h)
Cmax (mg / ml)
AUC last (mg / ml h)
T 1 / 2 (h)

Capecitabine

59-DFCR

59-DFUR

1
(0.5–3)
5.93
(1.97–24.26)
7.79
(3.38–14.58)
0.34
(0.20–0.56)

2
(0.5–3)
6.55
(2.94–8.27)
13.69
(7.99–18.37)
1.02
(0.61–1.44)

2
(0.5–3)
4.36
(3.26–6.73)
9.19
(7.37–11.91)
0.67
(0.56–1.37)

The data, presented as the median (range), are from four patients following their initial oral capecitabine dose of 1650 mg (750 mg / m 2 ),
n51, 2150 mg (1050 mg / m 2 ), n52, and 2450 mg (1200 mg / m 2 ), n51.
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